title: Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin.
abstract: Human adrenomedullin (AM) is a 52 amino acid peptide, which shares homology with the calcitonin gene-related peptide. Overexpression of AM in the prostate carcinoma cell line PC-3 results in growth inhibition with a 20% (for human AM) and 35% (for rat AM) increase in doubling time compared to parental or mock-transfected cells. We demonstrate by gene expression profiling that AM overexpression results in the dysregulation of approximately 100 genes. Examples of such genes include many involved in the formation of the cytoskeleton, cell adhesion and the extracellular matrix, as well as regulators of the cell cycle and apoptosis, cytokines and transcription factors. Several genes related to cell growth arrest, such as GADD45, IGF-BP6 and RUNX-3, are upregulated by AM. Interestingly, interleukin-13 receptor alpha 2 (IL-13R alpha 2) transcripts were significantly increased in clones overexpressing AM, which was confirmed by semiquantitative RT-PCR analysis. In addition, PC-3 cells treated with AM showed an overexpression of IL-13R alpha 2, which was abolished when cells were preincubated with an anti-AM blocking antibody. When PC-3 cells overexpressing AM and the IL-13R alpha 2 were treated with the highly specific IL13-PE38 cytotoxin, which binds to this receptor, a concentration-dependent inhibition of protein synthesis was observed. The IC(50) (concentration of cytotoxin inhibiting protein synthesis by 50%) ranged from 1 to 4 ng/ml. This cytotoxicity was specific as it was neutralized by the excess of IL-13 and confirmed by clonogenic assays. This study describes a novel AM-induced mechanism of tumor sensitization through the upregulation of functional IL-13R alpha 2 chain, an ideal target for the highly specific recombinant chimeric cytotoxin IL13-PE38.
authors.affiliation: Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Oscar
authors.initials: O
authors.lastname: Gonzalez-Moreno
authors.forename: Alfonso
authors.initials: A
authors.lastname: Calvo
authors.forename: Bharat H
authors.initials: BH
authors.lastname: Joshi
authors.forename: Ibane
authors.initials: I
authors.lastname: Abasolo
authors.forename: Pamela
authors.initials: P
authors.lastname: Leland
authors.forename: Zhou
authors.initials: Z
authors.lastname: Wang
authors.forename: Luis
authors.initials: L
authors.lastname: Montuenga
authors.forename: Raj K
authors.initials: RK
authors.lastname: Puri
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Green
mesh_terms: D053607:Adrenomedullin; D017209:Apoptosis; D002453:Cell Cycle; D020869:Gene Expression Profiling; D006801:Humans; D053661:Interleukin-13 Receptor alpha1 Subunit; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D010455:Peptides / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D018123:Receptors, Interleukin / Q000096:biosynthesis* / Q000235:genetics* / Q000502:physiology; D053660:Receptors, Interleukin-13; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
chemical_list: C508181:IL13RA1 protein, human; C508185:Il13ra1 protein, rat; D053661:Interleukin-13 Receptor alpha1 Subunit; D010455:Peptides; D018123:Receptors, Interleukin; D053660:Receptors, Interleukin-13; D053607:Adrenomedullin